FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of FDA Peptide Reclassification 2026: What It Means for Providers FDA Moves to Reevaluate Several Peptides American Med Spa Association BPC 157 & TB 500 Peptide Therapy for Injury Recovery Sanctuary Wellness